These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 27922336)

  • 1. Abscopal regression following SABR for non-small-cell-lung cancer: A case report.
    Cong Y; Shen G; Wu S; Hao R
    Cancer Biol Ther; 2017 Jan; 18(1):1-3. PubMed ID: 27922336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
    Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
    Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
    [No Abstract]   [Full Text] [Related]  

  • 3. Novel stereotactic body radiation therapy (SBRT)-based partial tumor irradiation targeting hypoxic segment of bulky tumors (SBRT-PATHY): improvement of the radiotherapy outcome by exploiting the bystander and abscopal effects.
    Tubin S; Popper HH; Brcic L
    Radiat Oncol; 2019 Jan; 14(1):21. PubMed ID: 30696472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing SABR delivery for synchronous multiple lung tumors using volumetric-modulated arc therapy.
    Tekatli H; Tetar SU; Nguyen TK; Warner A; Verbakel WF; Palma DA; Dahele M; Gaede S; Haasbeek C; Spoelstra FO; de Haan PF; Slotman BJ; Senan S
    Acta Oncol; 2017 Apr; 56(4):548-554. PubMed ID: 28358667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosimetric Comparison of Real-Time MRI-Guided Tri-Cobalt-60 Versus Linear Accelerator-Based Stereotactic Body Radiation Therapy Lung Cancer Plans.
    Wojcieszynski AP; Hill PM; Rosenberg SA; Hullett CR; Labby ZE; Paliwal B; Geurts MW; Bayliss RA; Bayouth JE; Harari PM; Bassetti MF; Baschnagel AM
    Technol Cancer Res Treat; 2017 Jun; 16(3):366-372. PubMed ID: 28168936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?
    Xing D; Siva S; Hanna GG
    Clin Oncol (R Coll Radiol); 2019 Jul; 31(7):432-443. PubMed ID: 31005381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus TomoTherapy.
    Xhaferllari I; El-Sherif O; Gaede S
    J Appl Clin Med Phys; 2016 Sep; 17(5):329-340. PubMed ID: 27685129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated Intensity-Modulated Radiotherapy for Patients With Non-Small-Cell Lung Cancer.
    Pollom EL; Qian Y; Durkee BY; von Eyben R; Maxim PG; Shultz DB; Gensheimer M; Diehn M; Loo BW
    Clin Lung Cancer; 2016 Nov; 17(6):588-594. PubMed ID: 27378172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
    Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
    Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
    Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
    Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A critical review of recent developments in radiotherapy for non-small cell lung cancer.
    Baker S; Dahele M; Lagerwaard FJ; Senan S
    Radiat Oncol; 2016 Sep; 11(1):115. PubMed ID: 27600665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic Effects of Radiation Therapy-Induced Abscopal Responses in Patients with Advanced Lung Cancer.
    D'Andrea MA; Reddy GK
    Oncology; 2021; 99(1):1-14. PubMed ID: 33221794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic ablative radiotherapy for ultra-central lung tumors: prioritize target coverage or organs at risk?
    Murrell DH; Laba JM; Erickson A; Millman B; Palma DA; Louie AV
    Radiat Oncol; 2018 Apr; 13(1):57. PubMed ID: 29606150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative planning study for lung SABR between tri-Co-60 magnetic resonance image guided radiation therapy system and volumetric modulated arc therapy.
    Park JM; Park SY; Kim HJ; Wu HG; Carlson J; Kim JI
    Radiother Oncol; 2016 Aug; 120(2):279-85. PubMed ID: 27401404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis.
    Foster CC; Sher DJ; Rusthoven CG; Verma V; Spiotto MT; Weichselbaum RR; Koshy M
    Radiat Oncol; 2019 Jan; 14(1):18. PubMed ID: 30691492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Blood Biomarkers for Response Prediction and Monitoring of Stereotactic Ablative Radiotherapy and Immunotherapy in Metastatic Oligoprogressive Lung Cancer.
    Zafra J; Onieva JL; Oliver J; Garrido-Barros M; González-Hernández A; Martínez-Gálvez B; Román A; Ordóñez-Marmolejo R; Pérez-Ruiz E; Benítez JC; Mesas A; Vera A; Chicas-Sett R; Rueda-Domínguez A; Barragán I
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
    Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
    J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy.
    Murray LJ; Thompson CM; Lilley J; Cosgrove V; Franks K; Sebag-Montefiore D; Henry AM
    Phys Med Biol; 2015 Feb; 60(3):1237-57. PubMed ID: 25590229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calculating the individualized fraction regime in stereotactic body radiotherapy for non-small cell lung cancer based on uncomplicated tumor control probability function.
    Lu JY; Lin PX; Huang BT
    Radiat Oncol; 2019 Jun; 14(1):111. PubMed ID: 31221159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forecasting the impact of stereotactic ablative radiotherapy for early-stage lung cancer on the thoracic surgery workforce.
    Edwards JP; Datta I; Hunt JD; Stefan K; Ball CG; Dixon E; Grondin SC
    Eur J Cardiothorac Surg; 2016 Jun; 49(6):1599-606. PubMed ID: 26796110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.